Lupin gets China nod for oseltamivir launch in 2026

Regulatory approval sets up Lupin’s first China launch

Lupin Limited said on May 22, 2026 that China’s National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate. The filing was done in partnership with Yabao Pharmaceuticals, which Lupin described as a leader in China’s paediatric medicine market. The approval is a milestone because it represents Lupin’s first product entry into China. For Lupin, this is positioned as a step in its broader global expansion strategy. The company said the product will be launched and commercialized to expand access, particularly for paediatric use. The development is notable in the context of increasing focus on geographic diversification by Indian pharmaceutical companies. Lupin’s announcement was issued from Mumbai and Beijing.

What was approved: oseltamivir oral suspension 6 mg/mL

The approved product is Oseltamivir Phosphate for oral suspension, with a strength of 6 mg/mL. Lupin also specified the strength as 6 mg (base)/mL in the indication statement. Oral suspensions are typically used where dosing flexibility is important, including in younger patients. Lupin said the launch and commercialization will focus on expanding access, particularly for paediatric use. The company framed the product as aligned with its stated commitment to delivering high-quality, affordable medicines. The announcement did not disclose a launch date, pricing, or manufacturing location for the China market. It also did not provide expected sales or market-share targets.

Indications highlighted for treatment and prevention of influenza

Lupin stated that Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL is indicated for two use cases. First, for treatment of influenza A and B in patients two weeks of age and older. Second, for prevention of influenza A and B in individuals one year of age and older. These indications underline the relevance of the product for paediatric care pathways, especially during seasonal influenza outbreaks. Lupin’s release did not mention any additional labeling details beyond these two points. It also did not refer to any specific public-health program or tender structure in China.

Partner angle: working with Yabao Pharmaceuticals

Lupin said the China approval was achieved in partnership with Yabao Pharmaceuticals. It described Yabao as a leader in China’s paediatric medicine market. The collaboration is presented as a route to local execution in a market that has its own regulatory and commercialization requirements. While the announcement confirms the partnership for the approved oseltamivir product, it does not specify whether Yabao will handle distribution, sales, or other operational responsibilities. It also does not describe financial terms of the partnership. Still, the choice of a paediatric-focused partner aligns with Lupin’s stated intent to expand access for children.

Management commentary on China entry

Fabrice Egros, President - Corporate Development, Lupin, linked the approval directly to market-entry strategy. He said, “We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world's largest pharmaceutical markets.” The statement indicates that Lupin sees China as a priority geography. The company’s release did not include additional quotes or guidance. It also did not comment on potential follow-on filings for other products, beyond previously disclosed China-related partnerships.

How this fits Lupin’s wider China plans

Alongside the oseltamivir approval, the provided material references Lupin’s earlier China-focused deal for a respiratory product. Lupin had announced on June 16, 2025 that it entered into a license and supply agreement with Sino Universal Pharmaceuticals (SUP) for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in China. Under that agreement, SUP would obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin would be the marketing authorization holder and responsible for manufacturing. This shows Lupin using partnership structures to build presence in China across therapy areas. The oseltamivir approval now becomes the first confirmed product entry for Lupin in China, as stated in the May 2026 announcement.

Other licensing moves referenced in the material

The material also notes additional licensing arrangements outside China. It mentions an exclusive licensing agreement with China’s Gan & Lee Pharmaceuticals for Bofanglutide, described as a fortnightly injectable GLP-1 drug for diabetes and obesity management in India. It also references a licensing agreement with Neopharmed for the gastroenterology brand Plasil, covering the Philippines and Brazil markets. These references, taken together, underline Lupin’s use of licensing and commercialization partnerships to expand product offerings across geographies. However, the oseltamivir approval remains the central regulatory event in the latest announcement.

Key facts at a glance

Timeline of China-linked updates mentioned

Market impact and what investors typically track next

The announcement is primarily regulatory, with Lupin confirming approval and intention to launch and commercialize the product in China. For investors, the next concrete items to watch would usually include the timing of launch, commercialization structure with the partner, and any disclosures on rollout scale. None of those specifics were included in the text provided. What is explicit is that Lupin is adding China to its list of markets with an approved product entry, which can matter for long-term geographic diversification. The material also references an earlier China agreement for Tiotropium DPI, indicating that Lupin’s China strategy spans more than one therapy area. Any near-term impact on financials cannot be quantified from the information provided because the announcement does not include revenue, margin, or volume guidance.

Conclusion

Lupin’s May 22, 2026 update confirms regulatory approval in China for Oseltamivir Phosphate oral suspension and sets up its first product entry into the country through a partnership with Yabao Pharmaceuticals. The company said it plans to launch and commercialize the product to expand access, particularly for paediatric use. Lupin’s management described the approval as a strategic step into one of the world’s largest pharmaceutical markets. Separately referenced partnerships, including a prior China agreement for Tiotropium DPI, suggest the company is building a broader China playbook through local collaborations. The next expected milestones, based on the announcement, would be launch and commercialization execution in China.